Folia Microbiologica

, Volume 43, Issue 5, pp 473–474 | Cite as

Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27

  • F. Asanuma
  • Y. Yamada
  • E. Kawamura
  • K. Lee
  • H. Kobayashi
  • T. Yamada
  • T. Suzuki
  • T. Kubota
Immunology 9th IWIDA International Workshop on Immunodeficient Animals Prague (Czech Republic) June 15–18, 1997
  • 54 Downloads

Abstract

The antitumor effect of paclitaxel, epirubicin, and both in combination was tested using R-27, an estrogen receptor-positive human breast carcinoma. In anin vivo study using nude mice both drugs showed an additive effect, whereas they showed a supraadditive pattern inin vitro MTT assay. The combination of paclitaxel and epirubicin may enhance the antitumor effect on breast carcinoma.

Keywords

Paclitaxel Nude Mouse Antitumor Effect Taxol Epirubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akutsu M., Kano Y., Tsunoda S., Suzuki K., Yazawa Y., Miura Y.: Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell linesin vitro.Eur. J. Cancer 31A, 2341–2346 (1995).PubMedCrossRefGoogle Scholar
  2. Hahn S.M., Liebmann J.E., Cook J., Fisher J., Goldspiel B., Venzon D., Mitchell J.B., Kaufman D.: Taxol in combination with doxorubicin or etoposide.Cancer 72, 2705–2711 (1993).PubMedCrossRefGoogle Scholar
  3. Kubota T., Matsuzaki S.W., Hoshiya Y., Watanabe M., Kitajima M., Asanuma F., Yamada Y., Koh J.: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.J. Surg. Oncol. 64, 115–121 (1997).PubMedCrossRefGoogle Scholar
  4. Lück H.J., Thomssen C., Dubois A., Lisboa B.W., Untch M., Kühnle H., Konecny G., Jänicke F., Meerpohl H.G., Lindner C., Hecker D., Diergarten K.: Interim analysis of phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.Seminars in Oncology 23, 33–36 (1996).PubMedGoogle Scholar
  5. Nawata H., Bronzert D., Lippman M.E.: Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.J. Biol. Chem. 256, 5016–5021 (1981).PubMedGoogle Scholar
  6. Steger G.G., Djavanmard M.P., Gnant M.F.X., Jakesz R.: Preoperative taxol induces objective responses in primary breast cancer not responding FEC treatment.Ann. Oncol. 5, 863–864 (1994).PubMedGoogle Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic 1998

Authors and Affiliations

  • F. Asanuma
    • 1
  • Y. Yamada
    • 1
  • E. Kawamura
    • 1
  • K. Lee
    • 2
  • H. Kobayashi
    • 3
  • T. Yamada
    • 4
  • T. Suzuki
    • 4
  • T. Kubota
    • 5
  1. 1.Department of SurgeryKitasato Institute HospitalTokyoJapan
  2. 2.Department of UrologyKitasato Institute HospitalTokyoJapan
  3. 3.Department of GynecologyKitasato Institute HospitalTokyoJapan
  4. 4.Biomedical LaboratoryKitasato Institute HospitalTokyoJapan
  5. 5.Department of SurgeryKeio University School of MedicineTokyoJapan

Personalised recommendations